Viking Therapeutics (NASDAQ:VKTX) Raised to “Sell” at BidaskClub

Viking Therapeutics (NASDAQ:VKTX) was upgraded by equities researchers at BidaskClub from a “strong sell” rating to a “sell” rating in a report issued on Wednesday, April 3rd, BidAskClub reports.

VKTX has been the subject of several other research reports. Maxim Group reduced their price objective on shares of Viking Therapeutics from $28.00 to $20.00 and set a “buy” rating for the company in a report on Thursday, March 14th. Leerink Swann started coverage on shares of Viking Therapeutics in a report on Friday, February 22nd. They issued a “market perform” rating and a $10.00 price objective for the company. William Blair reaffirmed an “outperform” rating on shares of Viking Therapeutics in a report on Friday, March 29th. Svb Leerink started coverage on shares of Viking Therapeutics in a report on Friday, February 22nd. They issued a “mkt perform” rating for the company. Finally, B. Riley started coverage on shares of Viking Therapeutics in a report on Tuesday, December 11th. They issued a “buy” rating and a $16.00 price objective for the company. One investment analyst has rated the stock with a sell rating, nine have assigned a buy rating and two have assigned a strong buy rating to the company. Viking Therapeutics currently has a consensus rating of “Buy” and an average price target of $22.54.

Shares of VKTX traded up $0.04 during midday trading on Wednesday, hitting $8.39. 2,049,763 shares of the stock traded hands, compared to its average volume of 3,325,767. Viking Therapeutics has a 1-year low of $3.69 and a 1-year high of $24.00. The company has a market cap of $604.32 million, a price-to-earnings ratio of -20.98 and a beta of 2.75.

Viking Therapeutics (NASDAQ:VKTX) last announced its quarterly earnings results on Wednesday, March 13th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.03. On average, equities analysts expect that Viking Therapeutics will post -0.45 EPS for the current fiscal year.

A number of institutional investors have recently modified their holdings of the business. Knott David M raised its position in Viking Therapeutics by 0.6% in the fourth quarter. Knott David M now owns 238,102 shares of the biotechnology company’s stock worth $1,821,000 after acquiring an additional 1,502 shares in the last quarter. Bank of New York Mellon Corp raised its holdings in Viking Therapeutics by 0.4% during the 4th quarter. Bank of New York Mellon Corp now owns 387,039 shares of the biotechnology company’s stock worth $2,960,000 after buying an additional 1,555 shares during the period. TIAA CREF Investment Management LLC raised its holdings in Viking Therapeutics by 1.6% during the 3rd quarter. TIAA CREF Investment Management LLC now owns 98,296 shares of the biotechnology company’s stock worth $1,712,000 after buying an additional 1,562 shares during the period. Court Place Advisors LLC raised its holdings in Viking Therapeutics by 18.5% during the 4th quarter. Court Place Advisors LLC now owns 12,800 shares of the biotechnology company’s stock worth $98,000 after buying an additional 2,000 shares during the period. Finally, Meeder Asset Management Inc. raised its holdings in Viking Therapeutics by 63.5% during the 4th quarter. Meeder Asset Management Inc. now owns 7,309 shares of the biotechnology company’s stock worth $56,000 after buying an additional 2,839 shares during the period. Hedge funds and other institutional investors own 65.56% of the company’s stock.

Viking Therapeutics Company Profile

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, which is in Phase II clinical trials to treat patients with non-alcoholic fatty liver disease and elevated low-density lipoprotein cholesterol.

Read More: Fiduciary

Analyst Recommendations for Viking Therapeutics (NASDAQ:VKTX)

Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.